

Pathology in France

Men and Money

Ph Camparo

Vice président

Syndicat des Medecins pathologistes Français

Centre de pathologie des Hauts de France

Pathology in France

- 438 Laboratories
- 1523 pathologists
- 62% women

- 188 Public Lab (

- 848 pathologists
- 70% de women

- 250 Private Lab

- 699 pathologists
- 54% women

Source document


Direction de la recherche, des études, de l'évaluation et des statistiques
DREES

Les médecins au 1er janvier 2012 Daniel SICART n° 167 – février 2012


Pathology in France

- 1,26 % of all specialists in private practice : 692 over 54643
- 3d less represented speciality after nephrology and neurosurgery
- 4d speciality with sex ratio in favor of women after gynecology dermatology and endocrinology
- 1,11 pathologists for 100 000 people
- (cardiologists 10,1/100000)
- Sources IRDES 2012

An population mainly of senior pathologists




A decreasing population



with a minimum expected in 2020

Pathologistes % 55 ans et plus




And expected decrease in number of laboratories

290
2012

250
2016

250
2016

2020 : 50
?



Concentration due to

- Age and diminution of pathologists
- Quality Insurance and accreditation
- Increased in diagnostic complexity (second opinion « experts »)
- Financial models (medical pathology)
- Cost and specificity of new technical tools (molecular biology, virtual imaging)


Financial evaluation of pathology

- From 1985 to 2013 : Montpellier system
- P= 0,27 €
- P100 : biopsies
- P120 small surgery, P200 « complex » surgery
- IHC P200 whatever the number of antibodies
- Cervical cytology P55
- In public practice : +P40 for each block after the 2nd + MIGAC (research only in public practice)


Financial evaluation of pathology

- Approximately 9 000 000 acts/year (cytology + histology)
- Slowly increasing
- 2006 : 9 354 674
- 2007 : 9 669 239 +3,4%
- 2008 : 9 955 022 +3%
- 2009 : 9 963 365 +0,1%
- 2010 : 9 948 444 – 0,1%

Tableau 3 - Evolution des honoraires des spécialistes d'ACP hors LABM



Pièces opératoires complexes et immunohistochimie en euros constant de janvier 1985 à décembre 2010



Financial evaluation of pathology

- In 2013 : CCAMV2
- Biopsies and small surgery : no change
- New evaluation of IHC fonction of number of antibodies (1-2, 3-6, 7-10 >10 : from 46 to 160 €)
- New evaluation of surgery for cancer (montpelier 54 €)
 - Colonic cancer 110 €
 - Cystoprostatectomy : 120 €
 - Duodenopancreatectomy : 140 €
 - Lymph node from 36 to 70 €
- Total expected +3%

Medical Costs

Health Care total : 186 Mds €

Surgical pathology : 0,400 Mds € (0,21%)

Medical pathology : 6 Mds €

Targeted therapies in oncology : 1,7Mds €,
(47% of all therapies in oncology)

Mean cost of targeted therapies 3200 €/month
(rapport Inca 2015)

→ 6000 € a month

Molecular pathology

Diagnosis : molecular platform (public actually 50% in CLCC) only




TABLEAU 4 Nombre de recherches de marqueurs prédictifs de la réponse à une thérapie ciblée, réalisés par les plateformes en 2014

PATHOLOGIE	BIOMARQUEUR	NOMBRE DE PATIENTS TESTÉS	POURCENTAGE DE TESTS POSITIFS ¹ »	THÉRAPIES CIBLÉES ASSOCIÉES
Cancer du sein	Amplification d' <i>HER2</i>	8 866	18,4 %	Trastuzumab Pertuzumab Lapatinib
Cancer de l'estomac	Amplification d' <i>HER2</i>	814	18,2 %	Trastuzumab
Cancer colorectal	Mutations de <i>KRAS</i>	22 011	44,2 %	Panitumumab Cetuximab
	Mutations de <i>NRAS</i>	18 085	4,7 %	
GIST	Mutations de <i>KIT</i>	1 189	61,6 %	Imatinib
	Mutations de <i>PDGFRA</i>	1 004	17,4 %	
Cancer du poumon	Mutations d' <i>EGFR</i>	24 558	10,5 %	Gefitinib Erlotinib Afatinib Osimertinib
	Translocation d' <i>ALK</i>	21 183	3,2 %	Crizotinib Ceritinib
	Translocation de <i>ROS1</i>	5 414	1,3 %	Crizotinib
Mélanome	Mutation de <i>BRAF V600</i>	5 534	34,8 %	Vemurafenib Dabrafenib Cobimetinib Trametinib
Leucémies	Détection de <i>BCR-ABL</i>	7 453	16,6 %	Imatinib Dasatinib Nilotinib
	Mutations d' <i>ABL</i>	785	21,5 %	Bosutinib Ponatinib

Cost : 130 M € in 2014

78000 tests in 2012, 117000 en 2014 +50%

27 millions €

In 2015

RIHN

Specific cotations for research diagnosis

180 M €

Main list with medical biology acts but secondary
list with molecular pathology

Not open to private practice !!

Conclusions

Income for pathologists in 2015

- Increase of income for pathologists in 2013-14 (+8%) because CCAMV2 (IHC and surgical oncology)
- But decrease in cytology (5 930 374 to 5 376 352 acts (-10%))
- mean 111 911 € (- 1,65% vs 2014)
- 12 over 32 (mean 105 772 €)
- 1st oncologists mean 240 395 € + 11%

Income for pathologists in 2015

- Still no source of funding for private diagnosis of molecular pathology
- Danger ++ :
- For patients
- For future of private pathology

Is this the twilight of private pathology ?

